載入...
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial
IMPORTANCE: Response patterns with immunotherapy may differ from those of other treatments. This warrants further investigation because some patients may benefit from continued immunotherapy beyond Response Evaluation Criteria in Solid Tumors (RECIST)-defined first progression. OBJECTIVE: To evaluat...
Na minha lista:
| 發表在: | JAMA Oncol |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5568541/ https://ncbi.nlm.nih.gov/pubmed/27243803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.0775 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|